贝达药业牵手西湖大学推动科技创新与产业创新深度融合

Core Insights - Bidda Pharmaceutical has signed a strategic cooperation agreement with Westlake University to focus on life sciences and pharmaceutical innovation, emphasizing student training, technological breakthroughs, platform construction, and achievement transformation [1][2] - The collaboration aims to enhance the entire chain from basic research to industrial application, reflecting the growing innovation environment in Hangzhou [1] Group 1: Company Initiatives - Bidda Pharmaceutical is a leading domestic innovative drug company that has established four funds to incubate nearly 30 cutting-edge projects across various fields, including small molecules, antibodies, gene/cell therapy, and CDMO [1] - The "Bidda Innovation Ecosystem Alliance" was established at the ninth Wanwu Growth Conference, aiming to integrate resources from industry, academia, research, healthcare, and investment to enhance collaborative efficiency [1] Group 2: Project Developments - The RGB-5088 pancreatic cell injection project, part of the ecosystem, received approval from the National Medical Products Administration to enter clinical trials on December 6, 2024, showcasing the ecosystem's ability to accelerate early-stage original projects [1] Group 3: Industry Environment - Hangzhou has implemented numerous supportive policies for innovative drugs and medical devices, creating a conducive environment for entrepreneurship and innovation [1] - The Yangtze River Delta Biopharmaceutical Industry Development Conference held in December last year fostered a consensus on collaboration among capital, technology, and industry, providing a broad platform for university-enterprise cooperation and achievement transformation [1]